Lista de obras - David Viola - Dominio Público Uruguay

Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center

scientific article published on 01 March 2020

An idic(15) associated with POF (premature ovarian failure): molecular cytogenetic definition of a case and review of the literature.

artículo científico

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer

artículo científico publicado en 2013

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

artículo científico publicado en 2014

BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer

artículo científico publicado en 2018

BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment

artículo científico publicado en 2017

BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer

artículo científico publicado en 2021

BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma

scientific article published on 29 November 2019

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

artículo científico publicado en 2008

Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST

artículo científico publicado en 2020

Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.

artículo científico publicado en 2013

Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience.

artículo científico publicado en 2018

DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER

scientific article published on 26 September 2019

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.

artículo científico publicado en 2015

Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases

artículo científico publicado en 2019

FoxP3 expression in papillary thyroid carcinoma: a possible resistance biomarker to iodine 131 treatment

artículo científico publicado en 2013

Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing

scientific article published on 26 September 2019

How to manage patients with differentiated thyroid cancer and a rising serum thyroglobulin level.

artículo científico publicado en 2014

In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.

artículo científico publicado en 2011

Incidental versus clinically evident thyroid cancer: a 5-year follow-up study

artículo científico publicado en 2012

KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease

artículo científico publicado en 2017

Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer

artículo científico publicado en 2019

Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan

artículo científico publicado en 2018

Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment

artículo científico publicado en 2018

Management of Medullary Thyroid Cancer

scientific article published on 26 December 2018

Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response

artículo científico publicado en 2020

Medullary thyroid carcinoma in children.

artículo científico

Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years

article

New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations.

artículo científico publicado en 2016

No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH

artículo científico publicado en 2020

Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up

artículo científico publicado en 2020

Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience.

artículo científico publicado en 2016

Papillary thyroid microcarcinoma and active surveillance

Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer.

artículo científico publicado en 2017

Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up

artículo científico publicado en 2013

Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation.

artículo científico publicado en 2016

Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study

artículo científico publicado en 2015

Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life

artículo científico publicado en 2017

Proteinuria is a late-onset adverse event in patients treated with cabozantinib

scientific article published on 03 May 2020

RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC).

artículo científico publicado en 2011

Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years

artículo científico

Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience

artículo científico publicado en 2017

Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy.

artículo científico publicado en 2009

Risk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular disease

artículo científico publicado en 2019

Role of YAP-1 in Thyroid Tumor Progression and Outcome.

artículo científico publicado en 2016

Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy

artículo científico publicado en 2009

Targeted Therapy in Thyroid Cancer: State of the Art.

artículo científico publicado en 2017

The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study

artículo científico publicado en 2012

The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer

artículo científico publicado en 2017

Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I

scientific article published on 26 May 2020

Treatment of advanced thyroid cancer with targeted therapies: ten years of experience

artículo científico publicado en 2016

Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?

artículo científico publicado en 2014

Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations

artículo científico publicado en 2019

Lista de obras de David Viola

Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center

An idic(15) associated with POF (premature ovarian failure): molecular cytogenetic definition of a case and review of the literature.

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer

BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment

BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer

BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST

Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.

Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience.

DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.

Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases

FoxP3 expression in papillary thyroid carcinoma: a possible resistance biomarker to iodine 131 treatment

Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing

How to manage patients with differentiated thyroid cancer and a rising serum thyroglobulin level.

In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.

Incidental versus clinically evident thyroid cancer: a 5-year follow-up study

KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease

Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer

Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan

Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment

Management of Medullary Thyroid Cancer

Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response

Medullary thyroid carcinoma in children.

Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years

New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations.

No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH

Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up

Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience.

Papillary thyroid microcarcinoma and active surveillance

Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer.

Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up

Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation.

Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study

Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life

Proteinuria is a late-onset adverse event in patients treated with cabozantinib

RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC).

Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years

Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience

Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy.

Risk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular disease

Role of YAP-1 in Thyroid Tumor Progression and Outcome.

Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy

Targeted Therapy in Thyroid Cancer: State of the Art.

The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study

The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer

Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I

Treatment of advanced thyroid cancer with targeted therapies: ten years of experience

Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?

Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations